The Latest Breaking News from Agilent Technologies

Agilent Technologies, a global laboratory technology provider, is driving growth in the Thai market where research investment is burgeoning through the support of new advanced technologies and collaboration with local partners.

Someone with a lot of money to spend has taken a bullish stance on Agilent Technologies (NYSE:A). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

 

Agilent Technologies (NYSE:A) has outperformed the market over the past 5 years by 5.5% on an annualized basis producing an average annual return of 15.19%. Currently, Agilent Technologies has a market capitalization of $35.66 billion.

Shares of the medical diagnostics and research company Agilent Technologies (A) have plunged nearly 30% year-to-date. However, Wall Street analysts see significant upside potential in the stock, given its solid fundamentals. So, is the stock a buy now? Read on to find out.

Agilent Technologies's (NYSE:A) short percent of float has fallen 32.77% since its last report. The company recently reported that it has 3.55 million shares sold short, which is 1.19% of all regular shares that are available for trading.

Agilent Technologies (NYSE:A) has outperformed the market over the past 10 years by 4.24% on an annualized basis producing an average annual return of 16.21%. Currently, Agilent Technologies has a market capitalization of $37.86 billion.

Agilent Technologies (NYSE:A) has outperformed the market over the past 10 years by 3.86% on an annualized basis producing an average annual return of 15.33%. Currently, Agilent Technologies has a market capitalization of $37.67 billion.

Agilent Technologies (NYSE:A) is set to give its latest quarterly earnings report on Tuesday, 2022-05-24. Here's what investors need to know before the announcement. Analysts estimate that Agilent Technologies will report an earnings per share (EPS) of $1.07.

Agilent Technologies's (NYSE:A) short percent of float has risen 30.22% since its last report. The company recently reported that it has 5.41 million shares sold short, which is 1.81% of all regular shares that are available for trading.

Integration of advanced technologies and analytics to early diagnosis of chronic diseases have helped companies engaged in the medical diagnostics and research industry gain wide market reach. This growing demand and rising investments should help prominent players in this space, Thermo Fisher Scientific (TMO) and Agilent Technologies (A), benefit. But…